TABLE 2.

Univariate and multivariate survival analyses of OS and PFS in patients with inoperable LA-NSCLC.

	OS						PFS
	Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
Age	0.902	0.526–1.546	0.708				0.840	0.534–1.323	0.452
Sex	0.476	0.229–0.991	0.047				0.901	0.525–1.548	0.706
Histology	1.062	0.608–1.855	0.832				0.878	0.553–1.394	0.581
T stage	0.721	0.523–0.996	0.047				0.986	0.785–1.237	0.901
N stage	1.598	1.139–2.242	0.007	1.435	1.036–1.987	0.030	1.398	1.090–1.794	0.008	1.354	1.064–1.722	0.014
Smoking index	2.359	1.344–4.141	0.003	1.937	1.037–3.617	0.038	1.242	0.788–1.959	0.351
Consolidation chemotherapy	1.562	0.900–2.714	0.113				1.025	0.627–1.677	0.921
KPS	0.808	0.459–1.422	0.460				0.842	0.527–1.345	0.472
Radiotherapy dose	1.730	1.013–3.031	0.046				1.493	0.929–2.398	0.098
Radiotherapy technique	1.596	0.923–2.761	0.095				1.049	0.661–1.663	0.840
Pretreatment hemoglobin	1.042	0.596–1.821	0.886				1.019	0.644–1.612	0.936
Pretreatment CEA	1.576	0.844–2.942	0.153				1.384	0.836–2.293	0.206
Immune signature	0.367	0.195–0.693	0.002	0.481	0.240–0.961	0.038	0.548	0.340–0.885	0.014	0.568	0.358–0.901	0.016

CEA, carcinoembryonic antigen; HR, hazard ratio; KPS, Karnofsky Performance Score; LA-NSCLC, locally advanced non-small-cell lung cancer; OS, overall survival; PFS, progression-free survival.